References
- Parker S L, Tong T, Bolden S, et al. Cancer statistics, 1996. CA: A Cancer Journal for Clinicians 1996; 65: 5–27
- Gittes R. Carcinoma of the prostate. N Engl J Med 1991; 324: 236–245
- Scher H I, Kelly W K. Flutamide withdrawal syndrome: its impact on clinical trials in hormone refractory prostate cancer. J Clin Oncol 1993; 11: 1566–1572
- Small E J, Srinivas S. The antiandrogen withdrawal syndrome: experience in a large cohort of unselected advanced prostate cancer patients. Cancer 1995; 15: 1428–1434
- Eisenberger M A, Simon R, O'Dwyer P J, et al. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostate carcinoma. J Clin Oncol 1985; 3: 827–841
- Tannock I F. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?. J Clin Oncol 1985; 3: 1013–1021
- Hudes G R, Greenberg R, Krigel R L. Phase II study of estramus-tine and vinblastine, 2 microtubule inhibitors in hormone refractory prostate cancer. J Clin Oncol 1992; 10(11)1754–1761
- Seidman A D, Scher H I, Petrylak D, et al. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostate cancer. J Urol 1992; 147: 931–934
- Pienta K J, Redman B, Hussain M, et al. Phase II evaluation of oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate. J Clin Oncol 1994; 12: 2005–2012
- Hudes G R, Nathan F E, Khater C, et al. Paclitaxel plus estramustine in metastatic hormone refractory prostate cancer. Semin Oncol 1995; 22: 41–45
- Sella A, Kilbourn R, Amato R, et al. Phase II study of ketocona-zole combined with weekly doxorubicin in patients with andro-gen-independent prostate cancer. J Clin Oncol 1994; 12: 683–688
- Small E J, Srinivas S, Egan B, et al. Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony stimulating factor for the treatment of hormone resistant prostate cancer. J Clin Oncol 1996; 14: 1617–1625
- Tannock I, Osoba D, Stockier M R, et al. Chemotherapy with mi-toxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer. A Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756–1764
- Kantoff P W, Conoway M, Winer E, et al. Hydrocortisone with or without mitoxantrone in patients with hormone refractory prostate cancer: preliminary results from a prospective randomized Cancer and Leukemia Group B Study (9182). Proc Am Soc Clin Oncol 1996; 15: 25
- Kobayashi K, Vokes E E, Vogelzang N J, et al. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol 1995; 13: 2196–2207
- Reyno L M, Egorin M J, Eisenberger M A, et al. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. J Clin Oncol 1995; 13: 2187–2195
- Kelly W K, Curley T, Liebertz C, et al. Prospective evaluation of hydrocortisone and suramin in patients with androgen-indepen-dent prostate cancer. J Clin Oncol 1995; 13: 2208–2213
- Jackson R C, Leopold W R, Sebolt J S. Biochemical and experimental chemotherapy studies of the pyrazoloacridines. Proc Am Assoc Cancer Res 1988; 29: 536
- Jackson R C, Sebolt J S, Shillis J L, et al. The pyrazoloacridines: approaches to the development of a carcinoma-selective cytotoxic agent. Cancer Invest 1990; 8: 39–47
- Lorusso P, Wozniak A J, Polin L, et al. Antitumor efficacy of PD1 15934 (NSC 366140) against solid tumors of mice. Cancer Res 1990; 50: 4900–4905
- Sebolt J S, Leopold W R, Hamelehle K L, et al. Solid tumor selectivity of the 2-aminoalkyl-t-nitro-pyrazolo [3,4,5]acridines. a novel class of DNA-binding antitumor agents. Proc Am Assoc Cancer Res 1986; 27: 421
- Sebolt J S, Scavone S V, Pinter C D, et al. Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro. Cancer Res 1987; 47: 4299–4304
- Sebolt J, Havlick M, Hamelehle K, et al. Activity of the pyrazoloacridines against multidrug-resistant tumor cells. Cancer Chemother Pharmacol 1989; 24: 219–224
- Sebolt-Leopold J S, Scavone S V. Biochemistry of the interactions between DNA and the pyrazoloacridines, a series of biologically novel anticancer agents. Proc Am Assoc Cancer Res 1991; 32: A1980
- Rowinsky E, Grochow L, McGuire W, et al. Phase I pharmacologic study of pyrazoloacridine (PA), a novel acridine compound, on a single 1–3 hour schedule. Proc Am Soc Clin Oncol 1993; 12: 160
- Kelly W K, Scher H I, Mazamudar M. Prostate-specific antigen as a measure of disease outcome in metastatic hormone refractory prostate cancer. J Clin Oncol 1993; 11(4)607–615